Sort
82,697 grants matching “vaccine development”
Evaluation of the Immunogenicity and Efficacy of a DNA Prime/Protein Boost Vaccine
$715,267Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2017 · AI
Using Lipids for Vaccination
$715,234Luc Teyton · Scripps Research Institute, The · U01 · FY2007 · AI
Inflammatory Organ Injury after Pneumonia-Derived Sepsis
$715,216Samithamby Jeyaseelan · Louisiana State Univ A&M Col Baton Rouge · R01 · FY2024 · AI
Inflammatory Organ Injury after Pneumonia-Derived Sepsis
$715,216Samithamby Jeyaseelan · Louisiana State Univ A&M Col Baton Rouge · R01 · FY2025 · AI
RNA METABOLISM IN TRYPANOSOMES
$715,160Elisabetta Ullu · Yale University · R37 · FY2012 · AI
RNA METABOLISM IN TRYPANOSOMES
$715,160Christian Tschudi · Yale University · R01 · FY2014 · AI
Mucosal Protection Against HIV Generated by PIV5 Priming and VLP Boosting
$715,150Paul W. Spearman · Emory University · R01 · FY2016 · AI
Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection
$715,124Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2020 · AI
Parents, Pediatricians and Telephone Coaches Partner to Improve Control (PARTNER)
$715,076Jane M Garbutt · Washington University · R01 · FY2009 · HL
NK cell-mediated regulation of T cell immunity in TB/HIV co-infection
$715,070Cheryl Liane Day · Emory University · R01 · FY2015 · AI
NRSA Institutional Training Program in Oral Biology
$715,048Robert A Burne · University Of Florida · T32 · FY2010 · DE
Development of RhCMV Vectors for SIV Infection
$715,032Oregon Health And Science University · R01 · FY2004 · AI
Adjuvant Development
$715,000David Johnson · Corixa Corporation · N01 · FY2013 · AI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model
$714,959Karsten R.o. Hazlett · Albany Medical College · R01 · FY2019 · AI
Mechanisms of vaccine interference by S. aureus-induced imprints
$714,925George Y Liu · University Of California, San Diego · R01 · FY2025 · AI
T cell Immunity and the Outcome of Acute HCV Infection
$714,861Christopher M. Walker · Research Inst Nationwide Children'S Hosp · R01 · FY2020 · AI
COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder
$714,815Elaine L Hill · University Of Rochester · U01 · FY2023 · DA
Natural Killer cells and the Immunogenetics of COVID-19
$714,785Paul John Norman · University Of Colorado Denver · R01 · FY2022 · AI
microRNA Regulation of Gamma-herpesvirus Latency and Reactivation
$714,774Rebecca L Skalsky · Oregon Health & Science University · R01 · FY2022 · AI
REDES: a peer network and mobile health (mHealth) enhanced CHW model to maximize COVID-19 vaccination among low income Latinos
$714,762Kathleen R Page · Johns Hopkins University · R01 · FY2024 · MD
RepServer: Antigen Receptor Repertoire Analysis Pipelines via the WWW
$714,700Lindsay G. Cowell · Ut Southwestern Medical Center · R01 · FY2012 · AI
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
$714,696Natalie Exner Dean · University Of Florida · R01 · FY2019 · AI
HIV-1 VACCINES DESIGNED TO INDUCE MUCOSAL IMMUNITY
$714,678University Of California Davis · P51 · FY2004 · RR
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses
$714,651Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2020 · AI
Dengue-Zika: Correlates of Cross-Protection in Non-Human Primates
$714,650Carlos A Sariol · University Of Puerto Rico Med Sciences · R01 · FY2020 · AI